Suplmnt
Apigenin hero image
Apigenin

From Teacup to Mitochondria: How Apigenin Quietly Links Bedtime Calm to Cellular Energy

You wrap your hands around a warm cup of chamomile. Steam rises, the day settles—and somewhere between your eyelids and your cells, a small plant molecule begins two very different conversations: one with the brain's calming brakes, another with the cell's energy meters.

Evidence: Promising
Immediate: Within hours (mild calming, especially from tea/extracts)Peak: 2–8 weeksDuration: 8–12 weeks typical in anxiety studiesWears off: Gradually over weeks; relapse prevention not established

TL;DR

Gentle calming for anxiety and pre-sleep ease without drowsiness or heavy sedation

Apigenin—the quiet flavone in chamomile—can ease anxiety and pre-sleep rumination without heavy sedation, likely via GABA-A modulation. Early human data (promising) support chamomile extracts for anxiety, while separate mitochondrial/CD38/NAD+ findings remain exploratory for people.

Loading products...

Practical Application

Who May Benefit:

People with mild anxiety or a ruminating, pre‑sleep mind who prefer gentler options; those curious about NAD+ biology may follow emerging research but shouldn’t expect energy or longevity effects without human trials.

Who Should Be Cautious:

Individuals with ragweed/daisy‑family allergies (for chamomile products) or those taking narrow‑therapeutic‑index drugs (e.g., anticoagulants, immunosuppressants, raloxifene) unless medically supervised.

Dosing: In GAD studies: pharmaceutical‑grade chamomile extract standardized to apigenin glycosides, titrated from ~220–500 mg capsules to 1,000–1,500 mg/day for 8–12 weeks. Food sources (parsley, chamomile tea) deliver apigenin but produce low, short‑lived blood levels.

Timing: For wind‑down, evening dosing mirrors tradition; for daytime calm, divided doses are common in trials. Expect felt calm within hours, but allow 2–8 weeks for anxiety scores to shift.

Quality: Choose standardized extracts with third‑party testing; confirm the plant species (Matricaria chamomilla/recutita) and declared apigenin-glycoside content. Tea is gentle but variable; capsules offer consistency.

Cautions: Apigenin can inhibit drug‑clearing enzymes (notably glucuronidation). In animals it increased raloxifene exposure; case reports and NCCIH note potential interactions with warfarin/calcineurin inhibitors for chamomile products. Apigenin also inhibits aromatase in vitro; endocrine‑sensitive conditions or therapies warrant caution.

The botanical whisper most people miss

Chamomile's reputation stretches from ancient Egypt to your kitchen shelf, but its steady hand often belongs to a single flavone: apigenin—a yellow plant compound abundant in chamomile flowers, parsley, and celery. Even its name nods to its roots: "apigenin" derives from Apium, the celery/parsley family that helped introduce it to our diets. Modern analyses confirm these plants as core sources. [1]

A calm hand on the brain's brakes

In the mid-1990s, researchers separated chamomile's chemistry like a watchmaker laying out gears. One gear clicked straight into the brain's "ease-up" switch: the same receptor family benzodiazepines use to slow over-firing neurons. That gear was apigenin. It bound the benzodiazepine site on GABA-A receptors and produced anxiety-reducing behavior in animals—without the heavy muscle-relaxing drag of classic sedatives at usual doses. Think of it as a gentle tap on the brake rather than a full stop. [2]

Apigenin's GABA story didn't end there. Botanists later "followed the signal" in feverfew, isolating apigenin again by tracking fractions that grabbed those same calming receptors. [3] In mice, apigenin even deepened pentobarbital-induced sleep and nudged chloride channels—the ions that let GABA's quieting message flow—suggesting a plausible route for the familiar bedtime softness of chamomile. [4]

What happens in real people?

A team at the University of Pennsylvania put chamomile extract (standardized, pharmaceutical-grade) to a modern test: an 8-week randomized, double-blind, placebo-controlled trial in mild-to-moderate generalized anxiety disorder. The chamomile group improved more than placebo on the standard Hamilton Anxiety Rating Scale—modest, but meaningful for an herb used for centuries. [5] A longer study followed: 12 weeks of open-label chamomile for GAD, then 26 weeks randomized to continue or switch to placebo. Symptoms eased during treatment, and though relapse prevention wasn't statistically superior overall, the extract remained safe and symptom-reducing while taken. [6]

Sleep is trickier. In a pilot trial of chronic primary insomnia, chamomile showed mixed, modest signals—some daytime function improved, but standard sleep metrics didn't budge consistently. [7] The U.S. National Center for Complementary and Integrative Health sums up the state of things plainly: "There's very little information on chamomile's effect on insomnia." [8] Yet a 2019 meta-analysis hints at a pattern many tea drinkers recognize: sleep quality (how restful nights feel) may improve, even if hard outcomes like total sleep time do not. Early benefits in GAD symptoms appeared by weeks two to four. [9]

The second storyline: refueling the cell's batteries

Here's the twist: apigenin also shows up in a discourse far from sleep and stress—NAD+ metabolism. NAD+ is the cell's universal coin for energy reactions. With age and chronic inflammation, one enzyme, CD38, behaves like a slow leak, chipping away at NAD+ reserves. In landmark experiments, apigenin inhibited CD38, raising intracellular NAD+ and shifting protein chemistry toward resilience in cells; in obese mice, apigenin improved glucose and lipid handling while boosting hepatic NAD+. [10]

Zoom out and you see why this matters: senescent (worn-out) cells secrete inflammatory signals that induce CD38 in nearby cells, linking inflammaging to NAD+ decline. Break that cycle, and you potentially protect mitochondrial defenses. In diabetic rats, apigenin's CD38 inhibition restored the NAD+/NADH ratio, revived Sirt3 (a mitochondrial tune-up enzyme), and reduced kidney stress. [11][12]

Is this real-world ready? Not yet. It's a compelling mechanistic trail—from enzyme to mitochondria to metabolism—but still needs human trials with isolated apigenin targeting CD38. [13]

A scientist's "aha" moment

When Ohio State scientists tested apigenin against one of cancer's favorite tricks—warping gene "splicing" to dodge cell death—they saw the molecule act like an editor returning a manuscript to its proper ending. "In its relationship with a set of specific proteins, apigenin re-establishes the normal profile in cancer cells," said associate professor Andrea Doseff, calling it a promising prevention strategy. [14] It's a story about breadth: unlike drugs that hit a single target, this nutrient brushes many proteins, sometimes nudging complex systems back toward healthy defaults.

The practical bridge between cup and capsule

Two realities shape apigenin use:

  • Food gives you milligrams; blood sees nanomoles. After a parsley-rich meal, peak blood apigenin averages ~0.13 micromoles/L, appearing many hours later and vanishing by a day—enough to prove absorption, but probably too low for many lab-observed effects. [15]
  • Standardized extracts concentrate the signal. In the GAD trials, chamomile extracts delivered 220–500 mg per capsule (titrated to 1–1.5 g/day, standardized to apigenin glycosides), taken for 8–12 weeks—an approach more consistent than tea. [5][6]

A pharmacology analysis suggests that while "heroic" amounts of food aren't practical, semi-purified apigenin supplements can plausibly reach therapeutic blood levels, depending on formulation. [16]

If you experiment, many people take chamomile extract in the evening for wind-down or divide doses for daytime calm. Expect any meaningful anxiety shift over 2–8 weeks, not overnight; the bedtime ease you feel on day one is the gentle GABA nudge, not a cure. [4][5][9]

Sensible cautions, real interactions

Plant molecules are not inert. Apigenin can interfere with drug processing enzymes (especially glucuronidation): in animals it boosted the oral exposure of the osteoporosis drug raloxifene, a sign that co-administration could raise levels of medications with narrow safety windows. [17] Test-tube work also shows apigenin can inhibit aromatase, the enzyme that makes estrogens from androgens—interesting, but not validated as a clinical effect. [18] And if your chamomile comes from the daisy family, remember classic ragweed-related allergies. NCCIH also notes scattered reports of interactions (e.g., warfarin, cyclosporine) with chamomile products. [8]

Why tradition noticed—and what's next

Traditions that leaned on chamomile weren't wrong; they were observing an herb that quietly presses the brain's calm button and, as we're now learning, talks to the cell's energy bookkeeping. The sleep/anxiety evidence in humans is modest but real, especially for perceived sleep quality and GAD symptoms. [5][6][7][9] The NAD+/CD38 story is still preclinical but intriguing, a rare case where a kitchen molecule brushes a hallmark of aging. [10][11][12][13]

"There's very little information on chamomile's effect on insomnia." — National Center for Complementary and Integrative Health, 2024. [8]

That honesty is the point. The next step is well-designed human trials of isolated apigenin—with smart delivery systems—to test whether the mitochondrial promise shows up in muscles, brains, and sleep. Until then, chamomile remains what it has always been: a gentle ally for the wired-and-tired mind, and a reminder that sometimes the smallest molecules are carrying two stories at once.

Key Takeaways

  • Apigenin, a flavone abundant in chamomile, parsley, and celery, engages the benzodiazepine site on GABA-A receptors, promoting calm without strong motor sedation at typical doses.
  • Standardized chamomile extract rich in apigenin glycosides reduced generalized anxiety symptoms versus placebo in humans, with benefits emerging over weeks.
  • Apigenin inhibits CD38 and raises NAD+ in obese mice, linking this calming molecule to mitochondrial/metabolic signaling; human energy or longevity effects are unproven.
  • Practical dosing in trials used standardized chamomile extract titrated from about 220–500 mg capsules up to 1,000–1,500 mg/day for 8–12 weeks.
  • Timing: take in the evening for wind-down or divide across the day for steady calm; felt effects may appear within hours, but allow 2–8 weeks for score changes.
  • Cautions: apigenin can inhibit drug-clearing enzymes and has reported interactions with warfarin and calcineurin inhibitors; its aromatase inhibition suggests added caution in endocrine-sensitive contexts.

Case Studies

8-week RCT: standardized chamomile extract vs placebo in mild–moderate GAD showed modest but significant anxiety reduction.

Source: J Clin Psychopharmacol. 2009;29(4):378–382. [5]

Outcome:Greater decrease in HAM-A scores with chamomile; good tolerability.

38-week study: 12 weeks open-label chamomile for GAD, then 26-week double-blind continuation vs placebo.

Source: Phytomedicine. 2016;23:1735–1742 (PMC5646235). [6]

Outcome:Symptom reduction during treatment; continuation safe; no significant advantage for relapse prevention.

Randomized pilot in chronic primary insomnia using chamomile extract.

Source: BMC Complement Altern Med. 2011;11:78. [7]

Outcome:Mixed, modest effects (some daytime function improved; core sleep metrics inconsistent).

Expert Insights

""In its relationship with a set of specific proteins, apigenin re-establishes the normal profile in cancer cells."" [14]

— Andrea Doseff, PhD, The Ohio State University OSU press release on apigenin and splicing in breast cancer cells (2013)

""There's very little information on chamomile's effect on insomnia."" [8]

— National Center for Complementary and Integrative Health (NCCIH) Federal evidence review (fact sheet updated Nov 2024)

Key Research

  • Apigenin binds the benzodiazepine site on GABA-A receptors and reduces anxiety-like behavior in animals without strong motor sedation at typical doses. [2]

    1995 fractionation of chamomile isolated apigenin as the active benzodiazepine-site ligand producing anxiolysis in mice.

    Provides a mechanistic bridge from traditional calm to receptor-level action.

  • In humans with generalized anxiety disorder, standardized chamomile extract (rich in apigenin glycosides) reduced symptoms versus placebo; benefits emerged within weeks. [5]

    University of Pennsylvania RCT (8 weeks) followed by a longer continuation study.

    Translates preclinical signal into clinical relief, albeit modest.

  • Apigenin inhibits CD38, raises NAD+, and improves metabolic readouts in obese mice; CD38 is upregulated by senescent-cell signals and tied to age-related NAD+ decline. [10]

    Cell and mouse work in Diabetes (2013) plus mechanistic aging studies linking senescence, CD38, and NAD+.

    Suggests a second, cellular-energy pathway that could matter for aging and metabolic health.

A single molecule can be both a bedtime whisper and a mitochondrial memo. In apigenin we’re reminded that the borders between mind and metabolism are porous—and that wisdom sometimes arrives as a plant’s quiet insistence to keep looking deeper.

Common Questions

What dose and timeline are typical if I’m using chamomile/apigenin for anxiety?

Trials titrated standardized chamomile extract (rich in apigenin glycosides) up to 1,000–1,500 mg/day for 8–12 weeks, with benefits emerging over weeks and some calm felt within hours.

Will apigenin make me drowsy or groggy?

At typical doses it aims for gentle calm without heavy sedation, reflecting its GABA-A modulation seen in preclinical work and human experience with chamomile extracts.

When should I take it—daytime or evening?

Evening dosing mirrors traditional wind-down use; for daytime calm, divided doses are common in studies.

Can apigenin boost my energy by raising NAD+?

It inhibits CD38 and raises NAD+ in mice, hinting at mitochondrial effects, but human energy or longevity benefits have not been demonstrated.

Who should be cautious or avoid apigenin/chamomile extracts?

Those on drugs cleared by glucuronidation, warfarin, or calcineurin inhibitors, and people with endocrine-sensitive conditions, should use caution and consult a clinician.

Sources

  1. 1.
    Plant flavone apigenin: An emerging anticancer agent (sources in nature; etymology from Apium; chamomile as rich source) (2018) [link]
  2. 2.
    Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors‑ligand with anxiolytic effects (1995) [link]
  3. 3.
    Bioassay‑guided isolation of apigenin with GABA‑benzodiazepine activity from Tanacetum parthenium (2009) [link]
  4. 4.
    Enhancement of pentobarbital‑induced sleep by apigenin through chloride ion channel activation (2012) [link]
  5. 5.
    A randomized, double‑blind, placebo‑controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder (2009) [link]
  6. 6.
    Long‑term chamomile treatment for generalized anxiety disorder: a randomized clinical trial (2016) [link]
  7. 7.
    Preliminary examination of a standardized chamomile extract for chronic primary insomnia: randomized, placebo‑controlled pilot (2011) [link]
  8. 8.
    Chamomile: Usefulness and Safety (Fact Sheet, updated Nov 2024) (2024) [link]
  9. 9.
    Therapeutic efficacy and safety of chamomile for anxiety, GAD, insomnia, and sleep quality: systematic review and meta‑analysis (2019) [link]
  10. 10.
    Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38 (Diabetes) (2013) [link]
  11. 11.
    The NADase CD38 is induced by factors secreted from senescent cells (linking senescence to NAD+ decline) (2019) [link]
  12. 12.
    CD38 inhibition by apigenin ameliorates mitochondrial oxidative stress in diabetic rats (2020) [link]
  13. 13.
    A potent and specific CD38 inhibitor (78c) reverses age‑related NAD+ decline and metabolic dysfunction (mouse) (2018) [link]
  14. 14.
    The Compound in the Mediterranean Diet that Makes Cancer Cells ‘Mortal’ (OSU press release) (2013) [link]
  15. 15.
    Bioavailability of apigenin from apiin‑rich parsley in humans (2006) [link]
  16. 16.
    Does Oral Apigenin Have Real Potential…? (Frontiers in Pharmacology) (2021) [link]
  17. 17.
    Apigenin increases raloxifene exposure by inhibiting glucuronidation/sulfation in rats (2010) [link]
  18. 18.
    Inhibition of human estrogen synthetase (aromatase) by flavones (1984) [link]